In conclusion, we demonstrate that the novel drug candidate T12 targets mesenchymal GPBP (i.e. cGPBP) to disrupt the EMT-based chemoresistance of solid tumors including lung and breast cancer. This evidence concerns the gene GPBP1 and breast carcinoma.